argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
$398 million in first quarter global net product sales
FDA review ongoing for CIDP sBLA with PDUFA target action date of..
$398 million in first quarter global net product sales
FDA review ongoing for CIDP sBLA with PDUFA target action date of..
*Quarterly Operating Revenues of **$818.2 million**, up **16%* *Quarterly Net Income of **$53.1 million**, ROE of..
· *Q3 FY24** Bookings of $219.9 million; book-to-bill ratio of 1.06*
· *Q3 FY24** Revenue of $208.3 million; GAAP net loss..